title: Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.
abstract: OBJECTIVE
  To test the effectiveness and long term safety of cannabinoids in multiple sclerosis (MS), in a follow up to the main Cannabinoids in Multiple Sclerosis (CAMS) study.
  
  
  METHODS
  In total, 630 patients with stable MS with muscle spasticity from 33 UK centres were randomised to receive oral Delta(9)-tetrahydrocannabinol (Delta(9)-THC), cannabis extract, or placebo in the main 15 week CAMS study. The primary outcome was change in the Ashworth spasticity scale. Secondary outcomes were the Rivermead Mobility Index, timed 10 metre walk, UK Neurological Disability Score, postal Barthel Index, General Health Questionnaire-30, and a series of nine category rating scales. Following the main study, patients were invited to continue medication, double blinded, for up to 12 months in the follow up study reported here.
  
  
  RESULTS
  Intention to treat analysis of data from the 80% of patients followed up for 12 months showed evidence of a small treatment effect on muscle spasticity as measured by change in Ashworth score from baseline to 12 months (Delta(9)-THC mean reduction 1.82 (n = 154, 95% confidence interval (CI) 0.53 to 3.12), cannabis extract 0.10 (n = 172, 95% CI -0.99 to 1.19), placebo -0.23 (n = 176, 95% CI -1.41 to 0.94); p = 0.04 unadjusted for ambulatory status and centre, p = 0.01 adjusted). There was suggestive evidence for treatment effects of Delta(9)-THC on some aspects of disability. There were no major safety concerns. Overall, patients felt that these drugs were helpful in treating their disease.
  
  
  CONCLUSIONS
  These data provide limited evidence for a longer term treatment effect of cannabinoids. A long term placebo controlled study is now needed to establish whether cannabinoids may have a role beyond symptom amelioration in MS.
authors.affiliation: Department of Mathematics and Statistics, University of Plymouth, Room N16, ITTC Building, Tamar Science Park, Plymouth, Devon PL6 8BX, UK. john.zajicek@phnt.swest.nhs.uk
authors.forename: J P
authors.initials: JP
authors.lastname: Zajicek
authors.forename: H P
authors.initials: HP
authors.lastname: Sanders
authors.forename: D E
authors.initials: DE
authors.lastname: Wright
authors.forename: P J
authors.initials: PJ
authors.lastname: Vickery
authors.forename: W M
authors.initials: WM
authors.lastname: Ingram
authors.forename: S M
authors.initials: SM
authors.lastname: Reilly
authors.forename: A J
authors.initials: AJ
authors.lastname: Nunn
authors.forename: L J
authors.initials: LJ
authors.lastname: Teare
authors.forename: P J
authors.initials: PJ
authors.lastname: Fox
authors.forename: A J
authors.initials: AJ
authors.lastname: Thompson
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D018712:Analgesics, Non-Narcotic / Q000009:adverse effects* / Q000627:therapeutic use*; D002188:Cannabis / Q000737:chemistry; D006233:Persons with Disabilities; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology; D010919:Placebos; D010936:Plant Extracts / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018712:Analgesics, Non-Narcotic; D010919:Placebos; D010936:Plant Extracts